



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Jean-Charles Picaud
✉ jean-charles.picaud@chu-lyon.fr

RECEIVED 30 July 2025

ACCEPTED 01 August 2025

PUBLISHED 12 September 2025

CITATION

Picaud J-C, Claris O, Gil-Campos M, De La Cueva IS, Cornette L, Alliet P, Léké A, Castanet M, Piloquet H, de Halleux V, Mitanchez D, Vandenplas Y, Maton P, Jochum F, Olbertz D, Policarpo SN, Lavalle L, Fumero C, Rodriguez-Garcia P, Moll JM, Silva-Zolezzi I, Zemrani B, Hays NP, Sprenger N and Miranda-Mallea J (2025) Correction: Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, *B. infantis* LMG11588, and *B. lactis* CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trial. *Front. Nutr.* 12:1676657. doi: 10.3389/fnut.2025.1676657

COPYRIGHT

© 2025 Picaud, Claris, Gil-Campos, De La Cueva, Cornette, Alliet, Léké, Castanet, Piloquet, de Halleux, Mitanchez, Vandenplas, Maton, Jochum, Olbertz, Policarpo, Lavalle, Fumero, Rodriguez-Garcia, Moll, Silva-Zolezzi, Zemrani, Hays, Sprenger and Miranda-Mallea. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, *B. infantis* LMG11588, and *B. lactis* CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trial

Jean-Charles Picaud^{1,2*}, Olivier Claris³, Mercedes Gil-Campos⁴, Ignacio Salamanca De La Cueva⁵, Luc Cornette⁶, Philippe Alliet⁷, André Léké⁸, Mireille Castanet⁹, Hugues Piloquet¹⁰, Virginie de Halleux¹¹, Delphine Mitanchez¹², Yvan Vandenplas¹³, Pierre Maton¹⁴, Frank Jochum¹⁵, Dirk Olbertz¹⁶, Sergio Negre Policarpo¹⁷, Luca Lavalle¹⁸, Cecilia Fumero¹⁸, Paula Rodriguez-Garcia¹⁹, Janne Marie Moll¹⁹, Irma Silva-Zolezzi²⁰, Boutaina Zemrani²⁰, Nicholas P. Hays²⁰, Norbert Sprenger²¹ and Javier Miranda-Mallea²²

¹Department of Neonatology, Hôpital de La Croix-Rousse, Lyon, France, ²CarMen Laboratory, INSERM, INRA, Université Claude Bernard Lyon 1, Pierre-Bénite, Lyon, France, ³Department of Neonatology, Hôpital Femme Mère Enfants, Bron, France, ⁴Paediatric Metabolism Unit, Reina Sofia University Hospital, University of Córdoba, IMIBIC, CIBEROBN, Córdoba, Spain, ⁵Department of Pediatrics, Instituto Hispalense de Pediatría, Sevilla, Spain, ⁶Department of Neonatology, AZ Sint-Jan Hospital, Brugge, Belgium, ⁷Department of Pediatrics, Jessa Hospital, Hasselt, Belgium, ⁸Neonatal Medicine and Intensive Care, Centre Hospitalier Universitaire Amiens Picardie, Amiens, France, ⁹CIC INSERM U1404, Department of Pediatrics, Rouen University Hospital Charles Nicole, Rouen, France, ¹⁰Child Chronic Disease Service, Centre Hospitalier Universitaire de Nantes, Nantes, France, ¹¹Neonatology Division, Centre Hospitalier Universitaire de Liège – Centre Hospitalier Universitaire de la Citadelle, Liège, Belgium, ¹²Service de Néonatalogie, Centre Hospitalier Universitaire de Tours, Tours, France, ¹³KidZ Health Castle, Vrije Universiteit Brussel, UZ Brussel, Brussels, Belgium, ¹⁴Service Néonatal, Clinique CHC-Montlégia, Liège, Belgium, ¹⁵Department of Pediatrics, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany, ¹⁶Department of Neonatology, Klinikum Südstadt Rostock, Rostock, Germany, ¹⁷Department of Pediatrics, Hospital Quironsalud, Valencia, Spain, ¹⁸Clinical Research Unit, Nestlé Research, Lausanne, Switzerland, ¹⁹Cmbio, Copenhagen, Denmark, ²⁰Clinical and Nutritional Research Unit, Nestlé Product Technology Center – Nutrition, Vevey, Switzerland, ²¹Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland, ²²Department of Pediatrics, Hospital Vithas, Valencia, Spain

KEYWORDS

bifidobacteria, gastrointestinal tolerance, growth, gut health, microbiota

A Correction on

Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, *B. infantis* LMG11588, and *B. lactis* CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trial

by Picaud, J.-C., Claris, O., Gil-Campos, M., De La Cueva, I. S., Cornette, L., Alliet, P., Léké, A., Castanet, M., Piloquet, H., de Halleux, V., Mitanchez, D., Vandenplas, Y., Maton, P., Jochum, F., Olbertz, D., Policarpo, S. N., Lavalle, L., Fumero, C., Rodriguez-Garcia, P., Moll, J. M., Silva-Zolezzi, I., Zemrani, B., Hays, N. P., Sprenger, N., and Miranda-Mallea, J. (2025). *Front. Nutr.* 12:1628847. doi: 10.3389/fnut.2025.1628847

In the published article, there was an error in the Supplementary materials. Supplementary Tables S2, S3, and

S4 were omitted. In addition, Supplementary Figure S1, Supplementary Figure S2, and Supplementary Figure S3 were published without figure legends with the original version of this paper. To correct these errors, the files have been replaced with a consolidated file containing all the Supplementary Material in one document.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.